España
EXELObvio.
ROSG Pero es que vuelvo a decir que mucha gente llega a la fiesta cuando no queda hielo paa los gintonics de tantos que se han servido..... Ninguna empresa aguanta un paroxismo del 100% en 2 dias!!!!! Son pura especulación y hay que ser rápido y aprovecharse..... Pero ESPECULANDO!
http://www.google.com/finance?cid=697437
Candidato semanal....
Hola a todos, de cara a ASCO en que farma tomariais posicion esta semana? Llevo ARNA y no pienso soltaras hasta ver FDA, opinais que esta pegara pelotazo hasta arriba del todo?
Si no me equivoco, ese no es ninguno de tus upgrades, no?
Me imagino que lo diras por esto:
"XenoPort Submits Investigational New Drug Application for XP23829 as a Potential Treatment of RRMS"
(relapsing-remitting multiple sclerosis)
Madre mia, historico a mas de 60 y cotizando en 5.88, si lo ve framus....jaja
Media de PO segun yahoo 8.08 dolares.
Saludos!
Por último: XENOPORT, INC.
Para los que tengáis :
2. Sunesis Pharmaceuticals, Inc (SNSS): Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The Company is focused primarily on the development of vosaroxin (formerly voreloxin) for the treatment of acute myeloid leukemia (AML). It has built a cancer drug development organization committed to advancing its product candidate, vosaroxin, in multiple indications. Vosaroxin is an anti-cancer quinolone derivative (AQD)-a class of compounds that has not been used previously for the treatment of cancer.
Sunesis will present the poster titled "VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia" at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting.
The details of the abstracts and schedule can be found here.
Sunesis Pharmaceuticals has a market cap of $129.50 million and it is currently trading around $2.74 with a 52-week range of $1.01 to $3.19. The stock has 135.9% price performance for the year 2012.
Sunesis Pharmaceuticals Reports First Quarter 2012 Financial Results and Highlights
